Clinical trials: Advanced and/or Metastatic Solid Tumours
Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC
- Trial name
- NCT05753722
- Testing
- PRTH-101, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 79 people
- Sponsor
- Incendia Therapeutics
Solid Tumors
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous administration of XmAb662 monotherapy or in combination with pembrolizumab in subjects with advanced solid tumors and to…
- Trial name
- NCT05996445
- Testing
- XmAb662, Keytruda® (pembrolizumab)
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Xencor, Inc.
Urological Cancer, Solid Cancer
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and dose-expansion, non-randomized phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036…
- Trial name
- NCT07744243
- Testing
- SI-B036
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
- Trial name
- DUAL-NK-BC (NCT07486089)
- Testing
- Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or…
- Trial name
- NCT02457793
- Testing
- Cobimetinib, GDC-0994
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Solid Tumor, Breast Cancer
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
The study comprises two phases: Phase 1a and Phase 1b. The purpose of the study is to observe the safety， tolerability and efficacy of FS-1502.
- Trial name
- NCT03944499
- Testing
- FS-1502
- Where
- 12 sites in China
- Volunteers
- 161 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Solid Tumor, Advanced Cancer
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
- Trial name
- NCT04419532
- Testing
- DS-1055a
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo
Advanced Cancer, Cervical Cancer
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
This is a 2-part trial: a Phase 1, open-label, dose-escalation study in participants with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in participants with recurrent…
- Trial name
- NCT03104699
- Testing
- AGEN2034
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 211 people
- Sponsor
- Agenus Inc.
Colon Cancer Metastatic, Head and Neck Cancer Metastatic
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors.
- Conditions
- Colon Cancer Metastatic, Head and Neck Cancer Metastatic, Metastatic Non-Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NEO (NCT03265080)
- Testing
- ADXS-NEO, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Advaxis, Inc.
Malignant Solid Tumors
A Study of TAK-505 in Adults With Solid Tumors
Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells.
- Trial name
- NCT07436728
- Testing
- TAK-505
- Where
- 15 sites in United States
- Volunteers
- 151 people
- Sponsor
- Takeda
Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Evaluation of BL-M07D1 for injection in Phase I clinical study of safety, tolerability, pharmacokinetic Characteristics, and initial efficacy in patients with locally advanced or metastatic digestive tract tumors and other solid…
- Trial name
- NCT05631964
- Testing
- BL-M07D1
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Urothelial Carcinoma, Urothelial Carcinoma Bladder
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
This study will be conducted in adult subjects diagnosed with any form of an advanced or metastatic solid tumors including urothelial carcinoma for which standard therapy is no longer effective or is intolerable.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Bladder Cancer, Bladder Disease
- Trial name
- NCT04200963
- Testing
- IK-175, IK-175 and nivolumab
- Where
- 10 sites in United States
- Volunteers
- 78 people
- Sponsor
- Ikena Oncology
Solid Tumor Malignancies, EGFR Positive Solid Tumors
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab in…
- Conditions
- Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR
- Trial name
- NCT06960395
- Testing
- VIR-5525, Pembrolizumab
- Where
- 4 sites in United States, Australia
- Volunteers
- 450 people
- Sponsor
- Vir Biotechnology, Inc.
Tumors
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.
- Trial name
- AGUS (NCT00127829)
- Testing
- Gefitinib
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- AstraZeneca
Advanced Solid Cancer, Metastatic Solid Tumor
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
- Conditions
- Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
- Trial name
- NCT06666270
- Testing
- SYN818
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
The purpose of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care chemotherapy regimens in participants with advanced solid…
- Conditions
- Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
- Trial name
- NCT03920839
- Testing
- Retifanlimab, Gemcitabine, Cisplatin
- Sponsor
- Incyte Corporation
Neoplasms
A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
This open-label, multicenter, global Phase Ib study will evaluate the safety, tolerability and pharmacokinetics of intravenous (IV) dosing of MEHD7945A in combination with oral dosing of cobimetinib in patients with locally…
- Trial name
- NCT01986166
- Testing
- Cobimetinib, MEHD7945A
- Where
- 9 sites in United States, Spain
- Volunteers
- 23 people
- Sponsor
- Genentech, Inc.
Locally Advanced or Metastatic Solid Tumors
Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter, open label, sequential-cohort, dose escalation \& expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006 and to establish the Maximum Tolerated Dose…
- Trial name
- NCT03736850
- Testing
- CS3006
- Where
- China
- Volunteers
- 17 people
- Sponsor
- CStone Pharmaceuticals
Non-Small Cell Lung Cancer
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®) with or without chemotherapy.
- Trial name
- PROPEL (NCT03138889)
- Testing
- NKTR-214, Pembrolizumab, Cisplatin
- Where
- 38 sites in United States, Australia and 3 more
- Volunteers
- 162 people
- Sponsor
- Nektar Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.